Posted by Defense World Staff on Aug 10th, 2024
Research analysts at StockNews.com initiated coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX – Get Free Report) in a report issued on Saturday. The firm set a “hold” rating on the medical research company’s stock.
Accelerate Diagnostics Price Performance
AXDX stock opened at $1.45 on Friday. Accelerate Diagnostics has a 1-year low of $0.73 and a 1-year high of $7.44. The stock has a market capitalization of $31.97 million, a P/E ratio of -0.36 and a beta of 0.57. The business has a fifty day moving average price of $1.22 and a 200-day moving average price of $1.11.
Accelerate Diagnostics (NASDAQ:AXDX – Get Free Report) last released its quarterly earnings results on Wednesday, May 8th. The medical research company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by ($0.16). The business had revenue of $2.92 million during the quarter, compared to analyst estimates of $3.00 million. As a group, analysts anticipate that Accelerate Diagnostics will post -2.37 earnings per share for the current year.
Hedge Funds Weigh In On Accelerate Diagnostics
A hedge fund recently raised its stake in Accelerate Diagnostics stock. Griffin Asset Management Inc. grew its stake in Accelerate Diagnostics, Inc. (NASDAQ:AXDX – Free Report) by 11.0% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,354,254 shares of the medical research company’s stock after purchasing an additional 134,530 shares during the period. Griffin Asset Management Inc. owned approximately 6.25% of Accelerate Diagnostics worth $1,341,000 at the end of the most recent reporting period. 17.14% of the stock is currently owned by institutional investors.
About Accelerate Diagnostics
Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.
Featured Stories
- Five stocks we like better than Accelerate Diagnostics
- High Dividend REITs: Are They an Ideal Way to Diversify?
- The Cannabis Sector: Profitability Takes Center Stage
- Energy and Oil Stocks Explained
- Amazon’s Stock Plunge: Is a Prime Buying Opportunity Knocking?
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Buy the Dip in e.l.f. Beauty: Analysts Point to a New High
Receive News & Ratings for Accelerate Diagnostics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Accelerate Diagnostics and related companies with MarketBeat.com’s FREE daily email newsletter.
You might be interested in: